Equillium Inc
Research Equillium Inc (EQ) on Bullrun: market cap USD 138.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEQ
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 138.23M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 5.31M
- Free cash flow-USD 4.30M
Valuation Snapshot
latest market cap is USD 138.23M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 22.40M | -USD 22.79M | n/a | -0.39 | USD 30.28M | USD 719.00K | USD 28.60M |
| FY2024 | USD 41.10M | -USD 8.07M | -USD 19.11M | n/a | -0.23 | USD 18.09M | USD 384.00K | USD 19.06M |
| FY2023 | USD 36.08M | -USD 13.34M | -USD 21.83M | n/a | -0.38 | USD 23.22M | USD 824.00K | USD 22.57M |
| FY2022 | USD 15.76M | -USD 62.43M | -USD 9.01M | n/a | -1.85 | USD 59.11M | USD 8.95M | USD 31.94M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 138.23M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 95.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 26.67M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 25.29M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 36.41M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 111.05M | n/a | n/a | n/a |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Equillium Inc's market cap?
Equillium Inc's market capitalization is USD 138.23M.
What does Equillium Inc do?
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc.